Fremont, CA-based Zosano ($ZSAN) delivered bitter news to its investors on Monday evening, tipping off the market that Eli Lilly ($LLY) had bowed out of their osteoporosis partnership while it had also decided to halt work on a daily dosing program.
Full Answer
Where can I buy shares of ZSAN?
Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Why is zosano Pharma’s stock soaring?
In pre-market trading, the share price of Zosano Pharma (NASDAQ: ZSAN) stock is incredibly soaring nearly 3,000%. But the total value of all of the outstanding shares of ZSAN stock has actually declined. Why? That’s because Zosano implemented a reverse stock split that became effective today.
Is zosano Pharma efficiently growing its dividend?
Zosano Pharma does not have a long track record of dividend growth. In the past three months, Zosano Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,000.00 in company stock.
Is zosano Pharma Corporation (ZSAN) correctly measuring grams or micrograms?
—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms.
Is ZSAN a good investment?
Zosano Pharma Corp (NASDAQ:ZSAN) The 1 analysts offering 12-month price forecasts for Zosano Pharma Corp have a median target of 21.00, with a high estimate of 21.00 and a low estimate of 21.00. The median estimate represents a +1,017.02% increase from the last price of 1.88.
Will ZSAN get FDA approval?
04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission of the M207 (zolmitriptan transdermal ...
Why did Acasti Pharma stock drop?
Acasti Pharma stock dropped from $2.18 to under $1 in a single trading session. Valentine's Day turned out to be no sweeter for ACST stock. The stock fell further when the company posted a larger loss than expected. For the company's 2020 fiscal third quarter, it posted a loss of 14 cents per share.
Why did Zosano stock drop?
Fremont, CA-based Zosano ($ZSAN) delivered bitter news to its investors on Monday evening, tipping off the market that Eli Lilly ($LLY) had bowed out of their osteoporosis partnership while it had also decided to halt work on a daily dosing program.
What is Qtrypta?
Qtrypta is a proprietary formulation of zolmitriptan that utilizes Dermally-Applied Microarray (ADAM) technology (drug-coated microneedles) in development for the acute treatment of migraine.
What is AXS 07?
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan.
Will Acasti Pharma stock go up?
During the day the stock fluctuated 14.04% from a day low at $0.91 to a day high of $1.04. The price has fallen in 6 of the last 10 days and is down by -13.76% for this period....Predicted Opening Price for Acasti Pharma of Tuesday, May 10, 2022.Fair opening price May 10, 2022Current price$0.96$0.94 (Undervalued)
Will Acst reverse split?
Acasti Pharma, Inc. (ACST) will effect a one-for-eight (1-8) reverse split of its common stock. The reverse stock split will become effective on Tuesday, August 31, 2021. In conjunction with the reverse split, the CUSIP number will change to 00430K873.
What does Acasti Pharma do?
(ACST) Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
Is Zosano Pharma a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 2 ho...
When is Zosano Pharma's next earnings date?
Zosano Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zosano...
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) EPS for t...
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Shares of Zosano Pharma reverse split on Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of...
What price target have analysts set for ZSAN?
3 equities research analysts have issued 12-month target prices for Zosano Pharma's shares. Their forecasts range from $70.00 to $70.00. On average...
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the following people: Mr. Steven Lo , Sr. VP of Operations, Pres, CEO & Director (Age 55, Pay $534.08k)...
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Oragenics (OGEN) , Oragenics (OGEN) , Aileron Therapeutics (ALRN) , PhaseBio Pharmaceu...
What other stocks do shareholders of Zosano Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Aeterna Zentaris (AEZS...
When did Zosano Pharma IPO?
(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 p...
What is Zosano Pharma?
Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle...
How to calculate restricted stock?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
How long are futures trading delayed?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
What is Zosano Pharma?
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies.
Does Zosano sell products?
Zosano doesn't sell a product (yet). For the three months ended June 30, 2021, service revenue related to agreements with three pharmaceutical companies for feasibility studies. We expect service revenue to fluctuate based on the volume and activity of feasibility studies.
Is Zosano M207 a priority?
IMO, M207 remains at the forefront of Zosano's priorities, but vaccines, especially for COVID-19 and its variants, as well as the Influenza viruses that are particular to each hemisphere. Where Zosano and their suppliers, collaborators/partners stand at this point are not known (it's a secret..)
Did Zosano and Novo Nordisk end a deal?
Novo Nordisk ended a deal, initially, Zosano and Novo Nordisk were to engage in collaborative efforts to carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system.
When will Zosano's first quarter end?
FREMONT, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights.
Is Zosano a biopharmaceutical?
FREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain.
ZSAN: Proposed Public Offering
On Tuesday, the company announced the initiation of an underwritten public offering. The offering will comprise of units having ZSAN’s common stock shares along with warrants to buy its common stock, sold by the company.
Publication of Clinical Data
On January 05, the company announced the publication of its Phase 1 clinical trial data in the Journal of Vaccines and Immunology. The data was published in an article by the name “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System”.
ZSAN: Board Changes
On December 13, ZSAN announced some changes to its Board of Directors. Firstly, Elaine M. Yang was appointed to Board. Ms. Yang currently serves as the Chief Revenue Officer at Lyra Health Inc. Before this, she has also served at executive positions with Facebook as well as Genetech.
CEO has no clue
Ok I'm long and holding a lot on this, it does worry me about this CEO, remember they withheld information that cause the stock to tank last year, they knew the fda wanted and warned them about safety yet with held the information from shareholders, why did it take a week to issue a Pr about the IP and not even release one saying they have started trials? That would start a run up into data and stop this slow bleed, remember we have a huge shelf hanging with EFFECT form ready to go, so they could drop that anytime, I just think this CEO is not up to the job and comes across to me as sketchy to say the least.
NO DATA NO TALK
NO DATA NO TALK, COME ON, stop wrote bad informations. A lot of people cause that slow falling. The volume are very low actually that mean a lot of people keep share. ZSAN don't give according to the law they cannot say anything to the shareholders and it is quite normal otherwise it is case of insider trading. Stop call or email ZSAN.